PDE4B and psoriasis: Orismilast is a potent PDE4 inhibitor with high selectivity for the PDE4B and PDE4D subtypes and demonstrated significant efficacy versus placebo at Week 16 in patients with moderate‐to‐severe psoriasis, both for percentage change in PASI and proportions of patients achieving PASI75 and PASI90 [10, 11, 12].